XY Therapeutics ApS: Financial statements 2023
CVR: 41120681
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
XY Therapeutics ApS (CVR 41120681) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 361,632 and a net result of DKK -1,152,205 compared with DKK -2,384,371 the year before. That is a decrease of 42.3% compared with the year before. Equity in the 2023 report amounted to DKK -6,027,792. The company had 2 employees in the financial year.
- Gross Profit
- DKK 361,632
- Profit/Loss
- DKK -1,152,205
- Equity
- DKK -6,027,792
- Total Assets
- DKK 4,892,065
- Employees
- 2
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout XY Therapeutics ApS
XY Therapeutics ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2020. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Fertilitypro ApS. The management consists of Martin Blomberg Jensen. The company is owned by Holding Fertility4U ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,676,788 and a net result of DKK -2,096,400 compared with DKK -1,369,854 the year before. Equity in the 2025 report amounted to DKK -9,494,046.